ABOS (Acumen Pharmaceuticals) Ending Cash Position: $52.03 Mil (As of Mar. 2026)


ABOS Acumen Pharmaceuticals Inc ABOS
34 GF Score
Price $2.60
! 3 Warning Signs
View Full Analysis

What is Acumen Pharmaceuticals Ending Cash Position?

Acumen Pharmaceuticals ABOS -3.17% 34 Ending Cash Position is $52.03 Mil as of Mar. 2026. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Acumen Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 was $52.03 Mil.

Acumen Pharmaceuticals's quarterly Ending Cash Position increased from Sep. 2025 ($47.06 Mil) to Dec. 2025 ($54.22 Mil) but then declined from Dec. 2025 ($54.22 Mil) to Mar. 2026 ($52.03 Mil).

Acumen Pharmaceuticals's annual Ending Cash Position declined from Dec. 2023 ($67.12 Mil) to Dec. 2024 ($35.86 Mil) but then increased from Dec. 2024 ($35.86 Mil) to Dec. 2025 ($54.22 Mil).

Acumen Pharmaceuticals Ending Cash Position Related Terms

Acumen Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Acumen Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acumen Pharmaceuticals Ending Cash Position Chart

Acumen Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 122.16 130.10 67.12 35.86 54.22

Acumen Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.39 37.04 47.06 54.22 52.03
ABOS
34GF Score
Acumen Pharmaceuticals Inc ABOS
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acumen Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Acumen Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=35.859+18.361
=54.22

Acumen Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=54.22+-2.193
=52.03

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $52.03 Mil mean?
Acumen Pharmaceuticals (ABOS) has a Ending Cash Position of $52.03 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Acumen Pharmaceuticals and its competitors.
Is Acumen Pharmaceuticals' Ending Cash Position too high?
Acumen Pharmaceuticals' current Ending Cash Position is $52.03 Mil. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acumen Pharmaceuticals' Ending Cash Position compare to YDES and PYXS?
Acumen Pharmaceuticals' Ending Cash Position of $52.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Acumen Pharmaceuticals and its competitors. Acumen Pharmaceuticals's current Ending Cash Position is $52.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acumen Pharmaceuticals stock overvalued right now?
Acumen Pharmaceuticals (ABOS) has a current Ending Cash Position of $52.03 Mil. The current Ending Cash Position is $52.03 Mil. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current Ending Cash Position is $52.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acumen Pharmaceuticals Business Description

Address 1210-1220 Washington Street, Suite 210, Newton, MA, USA, 02465
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
34GF Score

Get the complete analysis for ABOS

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.60
Price